Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
The latest announcement is out from ARS Pharmaceuticals ( (SPRY) ).
ARS Pharmaceuticals announced preliminary financial results for the fourth quarter of 2024 and outlined its objectives for 2025, emphasizing the success of neffy, their intranasal epinephrine product. The company reported approximately $6.5 million in net product revenue for the quarter, with plans to expand commercial access and consumer awareness, aiming for over 80% insurance coverage by the third quarter of 2025. Notably, neffy has been added to major pharmacy formularies and a direct-to-consumer marketing campaign is set to launch in May 2025 to increase brand recognition and patient engagement.
More about ARS Pharmaceuticals
ARS Pharmaceuticals is a biopharmaceutical company focused on developing solutions for allergic reactions that may lead to anaphylaxis. Their primary product is neffy, an epinephrine nasal spray designed to empower patients and caregivers in managing severe allergic reactions.
YTD Price Performance: 4.95%
Average Trading Volume: 1,211,421
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $1.09B
Learn more about SPRY stock on TipRanks’ Stock Analysis page.
